Brokerages Set Context Therapeutics Inc. (NASDAQ:CNTX) Price Target at $5.40

Context Therapeutics Inc. (NASDAQ:CNTX) has earned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $5.40.

CNTX has been the topic of a number of recent analyst reports. Guggenheim began coverage on shares of Context Therapeutics in a research note on Thursday, September 18th. They set a “buy” rating and a $5.00 price target on the stock. Wall Street Zen upgraded Context Therapeutics to a “sell” rating in a report on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, October 8th. HC Wainwright lifted their target price on Context Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Cantor Fitzgerald started coverage on Context Therapeutics in a research report on Thursday, October 2nd. They set an “overweight” rating for the company.

Institutional Trading of Context Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Context Therapeutics by 4.0% during the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after buying an additional 134,449 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics in the third quarter worth $100,000. Finally, Clear Harbor Asset Management LLC raised its stake in shares of Context Therapeutics by 60.5% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after acquiring an additional 35,000 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Price Performance

CNTX opened at $1.27 on Thursday. Context Therapeutics has a 12 month low of $0.49 and a 12 month high of $1.55. The business has a 50-day moving average of $1.16 and a two-hundred day moving average of $0.93. The stock has a market capitalization of $116.69 million, a price-to-earnings ratio of -5.29 and a beta of 1.94.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Wednesday, November 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Equities research analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current year.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.